Activation of Janus kinase 1 confers poor prognosis in patients with non‑small cell lung cancer

Liu,Dan; Huang,Yi; Zhang,Li; Liang,Dong‑Ni; Li,Li

doi:10.3892/ol.2017.6690

Activation of Janus kinase 1 confers poor prognosis in patients with non‑small cell lung cancer

Authors:
- Dan Liu
- Yi Huang
- Li Zhang
- Dong‑Ni Liang
- Li Li
View Affiliations

Affiliations: Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China, Clinical Laboratory Department, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Affiliated Hospital of the University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan 610093, P.R. China, Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, P.R. China
Published online on: August 1, 2017 https://doi.org/10.3892/ol.2017.6690
Pages: 3959-3966
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The activation of Janus kinase 1 (JAK1) has been reported to occur in non‑small cell lung cancer (NSCLC), activating the JAK/signal transducers and activators of transcription cascade. However, the association between JAK1 activation and the prognostic value in NSCLC remains unclear. The present study initially investigated the association between expression of the activated form of JAK1 (p‑JAK1) and prognosis in patients with NSCLC. A cohort of 142 resected primary NSCLC tissue samples, including 74 adenocarcinoma (ADCC) and 68 squamous cell carcinoma samples, were analyzed. p‑JAK1 expression status was determined by immunohistochemistry. Evaluation of epidermal growth factor receptor (EGFR) gene amplification by fluorescence in situ hybridization was subsequently performed in 74 ADCC samples. The prognostic significance of p‑JAK1 expression and EGFR gene amplification were evaluated with univariate and multivariate survival analyses. Compared with normal lung tissue, p‑JAK1 expression level was significantly increased in NSCLC (P<0.001). Positive p‑JAK1 expression indicated a poor prognosis, particularly for patients in early stages (stage I/II, including tumor size <3 cm, Lymph node invasion N0/1; all P<0.05). p‑JAK1 expression was an independent predictor of a poor prognosis (P=0.022). The overall survival time for patients with positive p‑JAK1 expression and EGFR‑amplified tumors was significantly shortened compared with patients with tumors negative for one or both features (both features present vs. neither feature present, P<0.001). The results provided clinical evidence that the activation of JAK1 was an independent prognostic factor, particularly in early stage NSCLC. The combination of EGFR gene amplification and p‑JAK1 expression may be a novel target for the selection of individual therapy strategies and predicting the effects of therapy for NSCLC.

View Figures

View References

1	Peters S, Adjei AA, Gridelli C, Reck M, Kerr K and Felip E: ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23:(Suppl 7). vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Liu D, Huang Y, Chen B, Zeng J, Guo N, Zhang S, Liu L, Xu H, Mo X and Li W: Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer. 117:3763–3773. 2011. View Article : Google Scholar : PubMed/NCBI
4	Rawlings JS, Rosler KM and Harrison DA: The JAK/STAT signaling pathway. J Cell Sci. 117:1281–1283. 2004. View Article : Google Scholar : PubMed/NCBI
5	Constantinescu SN, Leroy E, Gryshkova V, Pecquet C and Dusa A: Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. Biochem Soc Trans. 41:1048–1054. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, Maria Murga, Penas E, Vater I, Jayne S, Dyer MJ, et al: Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 53:309–316. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wang SW and Sun YM: The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S and Sozen S: Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells. Oncol Lett. 7:755–763. 2014.PubMed/NCBI
9	Schindler C, Levy DE and Decker T: JAK-STAT signaling: From interferons to cytokines. J Biol Chem. 282:20059–20063. 2007. View Article : Google Scholar : PubMed/NCBI
10	Xie H, Bae H, Noh J, Eun JW, Kim JK, Jung KH, Ryu JC, Ahn YM, Kim SY, Lee SH, et al: Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma. 56:136–140. 2009. View Article : Google Scholar : PubMed/NCBI
11	Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, Yoo NJ and Lee SH: Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 14:3716–3721. 2008. View Article : Google Scholar : PubMed/NCBI
12	You Z, Xu D, Ji J, Guo W, Zhu W and He J: JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma. Clin Transl Oncol. 14:143–149. 2012. View Article : Google Scholar : PubMed/NCBI
13	Liu D, Huang Y, Zeng J, Chen B, Huang N, Guo N, Liu L, Xu H, Mo X and Li W: Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway. J Cancer Res Clin Oncol. 137:1629–1640. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J and Gandara DR: Southwest Oncology Group: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A southwest oncology group study. J Clin Oncol. 23:6838–6845. 2005. View Article : Google Scholar : PubMed/NCBI
15	Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH and Cho BC: High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res. 18:1760–1768. 2012. View Article : Google Scholar : PubMed/NCBI
16	Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y, Li W, Li L, Liu X, Zheng B, et al: Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer. 89:337–342. 2015. View Article : Google Scholar : PubMed/NCBI
17	Koh Y, Jang B, Jeon YK, Kim TM, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW and Heo DS: EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Jpn J Clin Oncol. 41:548–554. 2011. View Article : Google Scholar : PubMed/NCBI
18	UICC and IUAC: TNM classification of malignant tumours. Wiley; New York, NY: 2002
19	Travis W, Brambilla E, Muller-Hermlink H and Harris C: World Health Organization classification of tumoursPathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press; Lyon: 2004
20	NCCN: NCCN Clinical practice guideline in oncology-non-small cell lung cancer guideline 2004. http://www.nccn.org2004.
21	Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 125:860–865. 2006. View Article : Google Scholar : PubMed/NCBI
22	Varella-Garcia M: Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay. Diagn Pathol. 1:192006. View Article : Google Scholar : PubMed/NCBI
23	Murakami T, Takigawa N, Ninomiya T, Ochi N, Yasugi M, Honda Y, Kubo T, Ichihara E, Hotta K, Tanimoto M and Kiura K: Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer. 83:30–36. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009. View Article : Google Scholar : PubMed/NCBI
25	Torres AF, Nogueira C, Magalhaes J, Costa IS, Aragao A, Gomes Neto A, Martins F and Tavora F: Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution. Anal Cell Pathol (Amst). 2014:3529252014.PubMed/NCBI
26	Cordero JB, Stefanatos RK, Myant K, Vidal M and Sansom OJ: Non-autonomous crosstalk between the Jak/Stat and Egfr pathways mediates Apc1-driven intestinal stem cell hyperplasia in the Drosophila adult midgut. Development. 139:4524–4535. 2012. View Article : Google Scholar : PubMed/NCBI
27	Huang Y, Li X, Jiang J and Frank SJ: Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene. 25:7565–7576. 2006. View Article : Google Scholar : PubMed/NCBI